MersV1, PubMed, Corpus, bibRecord, 000316

Evaluating MERS-CoV Entry Pathways.

Identifieur interne : 000316 ( PubMed/Corpus ); précédent : 000315; suivant : 000317

Evaluating MERS-CoV Entry Pathways.

Auteurs : Enya Qing ; Michael P. Hantak ; Gautami G. Galpalli ; Tom Gallagher

Source :

Methods in molecular biology (Clifton, N.J.) [ 1940-6029 ] ; 2020.

RBID : pubmed:31883084

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging zoonotic pathogen with a broad host range. The extent of MERS-CoV in nature can be traced to its adaptable cell entry steps. The virus can bind host-cell carbohydrates as well as proteinaceous receptors. Following receptor interaction, the virus can utilize diverse host proteases for cleavage activation of virus-host cell membrane fusion and subsequent genome delivery. The fusion and genome delivery steps can be completed at variable times and places, either at or near cell surfaces or deep within endosomes. Investigators focusing on the CoVs have developed several methodologies that effectively distinguish these different cell entry pathways. Here we describe these methods, highlighting virus-cell entry factors, entry inhibitors, and viral determinants that specify the cell entry routes. While the specific methods described herein were utilized to reveal MERS-CoV entry pathways, they are equally suited for other CoVs, as well as other protease-dependent viral species.

DOI: 10.1007/978-1-0716-0211-9_2
PubMed: 31883084

Links to Exploration step

pubmed:31883084

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluating MERS-CoV Entry Pathways.</title>
<author><name sortKey="Qing, Enya" sort="Qing, Enya" uniqKey="Qing E" first="Enya" last="Qing">Enya Qing</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Maywood, IL, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hantak, Michael P" sort="Hantak, Michael P" uniqKey="Hantak M" first="Michael P" last="Hantak">Michael P. Hantak</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Maywood, IL, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Galpalli, Gautami G" sort="Galpalli, Gautami G" uniqKey="Galpalli G" first="Gautami G" last="Galpalli">Gautami G. Galpalli</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Maywood, IL, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gallagher, Tom" sort="Gallagher, Tom" uniqKey="Gallagher T" first="Tom" last="Gallagher">Tom Gallagher</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Maywood, IL, USA. tgallag@luc.edu.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:31883084</idno>
<idno type="pmid">31883084</idno>
<idno type="doi">10.1007/978-1-0716-0211-9_2</idno>
<idno type="wicri:Area/PubMed/Corpus">000316</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000316</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Evaluating MERS-CoV Entry Pathways.</title>
<author><name sortKey="Qing, Enya" sort="Qing, Enya" uniqKey="Qing E" first="Enya" last="Qing">Enya Qing</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Maywood, IL, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hantak, Michael P" sort="Hantak, Michael P" uniqKey="Hantak M" first="Michael P" last="Hantak">Michael P. Hantak</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Maywood, IL, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Galpalli, Gautami G" sort="Galpalli, Gautami G" uniqKey="Galpalli G" first="Gautami G" last="Galpalli">Gautami G. Galpalli</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Maywood, IL, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gallagher, Tom" sort="Gallagher, Tom" uniqKey="Gallagher T" first="Tom" last="Gallagher">Tom Gallagher</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Maywood, IL, USA. tgallag@luc.edu.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Methods in molecular biology (Clifton, N.J.)</title>
<idno type="eISSN">1940-6029</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging zoonotic pathogen with a broad host range. The extent of MERS-CoV in nature can be traced to its adaptable cell entry steps. The virus can bind host-cell carbohydrates as well as proteinaceous receptors. Following receptor interaction, the virus can utilize diverse host proteases for cleavage activation of virus-host cell membrane fusion and subsequent genome delivery. The fusion and genome delivery steps can be completed at variable times and places, either at or near cell surfaces or deep within endosomes. Investigators focusing on the CoVs have developed several methodologies that effectively distinguish these different cell entry pathways. Here we describe these methods, highlighting virus-cell entry factors, entry inhibitors, and viral determinants that specify the cell entry routes. While the specific methods described herein were utilized to reveal MERS-CoV entry pathways, they are equally suited for other CoVs, as well as other protease-dependent viral species.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">31883084</PMID>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1940-6029</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>2099</Volume>
<PubDate><Year>2020</Year>
</PubDate>
</JournalIssue>
<Title>Methods in molecular biology (Clifton, N.J.)</Title>
<ISOAbbreviation>Methods Mol. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Evaluating MERS-CoV Entry Pathways.</ArticleTitle>
<Pagination><MedlinePgn>9-20</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-0716-0211-9_2</ELocationID>
<Abstract><AbstractText>Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging zoonotic pathogen with a broad host range. The extent of MERS-CoV in nature can be traced to its adaptable cell entry steps. The virus can bind host-cell carbohydrates as well as proteinaceous receptors. Following receptor interaction, the virus can utilize diverse host proteases for cleavage activation of virus-host cell membrane fusion and subsequent genome delivery. The fusion and genome delivery steps can be completed at variable times and places, either at or near cell surfaces or deep within endosomes. Investigators focusing on the CoVs have developed several methodologies that effectively distinguish these different cell entry pathways. Here we describe these methods, highlighting virus-cell entry factors, entry inhibitors, and viral determinants that specify the cell entry routes. While the specific methods described herein were utilized to reveal MERS-CoV entry pathways, they are equally suited for other CoVs, as well as other protease-dependent viral species.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qing</LastName>
<ForeName>Enya</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Maywood, IL, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hantak</LastName>
<ForeName>Michael P</ForeName>
<Initials>MP</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Maywood, IL, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Galpalli</LastName>
<ForeName>Gautami G</ForeName>
<Initials>GG</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Maywood, IL, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gallagher</LastName>
<ForeName>Tom</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Maywood, IL, USA. tgallag@luc.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P01 AI060699</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Methods Mol Biol</MedlineTA>
<NlmUniqueID>9214969</NlmUniqueID>
<ISSNLinking>1064-3745</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Coronavirus (CoV)</Keyword>
<Keyword MajorTopicYN="Y">Endosome</Keyword>
<Keyword MajorTopicYN="Y">HR2 peptide</Keyword>
<Keyword MajorTopicYN="Y">IFITM3</Keyword>
<Keyword MajorTopicYN="Y">Middle East respiratory syndrome (MERS)</Keyword>
<Keyword MajorTopicYN="Y">Protease</Keyword>
<Keyword MajorTopicYN="Y">Protease inhibitor</Keyword>
<Keyword MajorTopicYN="Y">Pseudovirus</Keyword>
<Keyword MajorTopicYN="Y">Spike (S)</Keyword>
<Keyword MajorTopicYN="Y">TMPRSS2</Keyword>
<Keyword MajorTopicYN="Y">Transfection</Keyword>
<Keyword MajorTopicYN="Y">Viral entry</Keyword>
<Keyword MajorTopicYN="Y">Virus concentration</Keyword>
<Keyword MajorTopicYN="Y">Virus purification</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>12</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>12</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>12</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">31883084</ArticleId>
<ArticleId IdType="doi">10.1007/978-1-0716-0211-9_2</ArticleId>
<ArticleId IdType="pmc">PMC7121971</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Lancet Infect Dis. 2013 Oct;13(10):859-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23933067</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2018 Feb 26;92(6):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29263263</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15150417</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2008 Mar;82(5):2580-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18077706</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet Infect Dis. 2014 Feb;14(2):140-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24355866</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2013 Nov;19(11):1819-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24206838</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2016 Jan 1;351(6268):81-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26678874</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2016 Dec 16;91(1):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27733646</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Pathog. 2017 Jul 31;13(7):e1006546</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28759649</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2017 Nov;511:9-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28802158</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Viruses. 2014 Sep 26;6(9):3683-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25256397</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12262-12267</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27791014</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2009 Nov;83(21):11133-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19706706</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Annu Rev Virol. 2016 Sep 29;3(1):237-261</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27578435</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Gen Microbiol. 1956 Apr;14(2):290-314</Citation>
<ArticleIdList><ArticleId IdType="pubmed">13319635</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virus Res. 2015 Apr 16;202:120-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25445340</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biol Chem. 2009 Aug 28;284(35):23177-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19487698</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2006 Jun;80(12):5768-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16731916</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>mBio. 2017 Apr 4;8(2):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28377531</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Adv Virus Res. 2016;96:29-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27712627</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>East Mediterr Health J. 2013;19 Suppl 1:S12-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23888790</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):E3119-E3128</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28348219</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000316 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000316 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:31883084
   |texte=   Evaluating MERS-CoV Entry Pathways.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:31883084" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Evaluating MERS-CoV Entry Pathways.

Evaluating MERS-CoV Entry Pathways.

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki